TrialBMC cancer2019

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Axel Heidenreich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.